This compound is a quinazoline-based derivative identified as an impurity of the active pharmaceutical ingredient afatinib. It is characterized by a dichloroaniline moiety and an oxolan-3-yloxy substituent, with stereochemistry specified at one chiral center.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
(S,E)-N-(4-((4-CHLORO-3-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-4-(DIMETHYLAMINO)BUT-2-ENAMIDE
pharmaceutical raw material
(S,E)-N-(4-((3,4-Difluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide (Afatinib Impurity)
pharmaceutical raw material
Afatinib Impurity 18
pharmaceutical intermediate
Calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-(2,3,4,5,6-pentadeuteriophenyl)-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
pharmaceutical raw material
Ipratropium bromide
pharmaceutical raw material
Bromocriptine mesylate
pharmaceutical raw material
Val-Cit-PAB-Exatecan
pharmaceutical raw material
(E)-N-[4-(3,4-dichloroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
GMLBQFFEIVQHIS-CWDCEQMOSA-N
CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)Cl)Cl)O[C@H]4CCOC4
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.